MIN-202
MIN-202 (also known as JNJ-42847922, JNJ-922) is a selective, small-molecule antagonist of the OX2 receptor that is under development by Minerva Neurosciences and Johnson & Johnson's Janssen Pharmaceutica for the treatment of insomnia and major depressive disorder (MDD).[1][2][3] As of December 2015, it is in phase II clinical trials for both insomnia and MDD.[4][5][2] The chemical structure of MIN-202 has yet to be disclosed.
See also
References
- ↑ Christopher, John A (2014). "Small-molecule antagonists of the orexin receptors". Pharmaceutical Patent Analyst 3 (6): 625–638. doi:10.4155/ppa.14.46. ISSN 2046-8954.
- 1 2 Zisapel, Nava (2014). "Current Phase II investigational therapies for insomnia". Expert Opinion on Investigational Drugs: 1–11. doi:10.1517/13543784.2015.987340. ISSN 1354-3784.
- ↑ Cristoph Boss, Catherine Ross (2015). "Recent Trends in Orexin Research – 2010 to 2015". ScienceDirect. doi:10.1016/j.bmcl.2015.05.012.
- ↑ "JNJ 42847922". AdisInsight. Retrieved 2015-05-19.
- ↑ Medicines in Development for Mental Health (PDF) (Report). Pharmaceutical Research and Manufacturers of America. 2014. Retrieved 2015-05-19.
Further reading
- Discovery of JNJ-42847922, a Selective Orexin-2 Antagonist for the Treatment of Insomnia Disorder (page 216)
- Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia (page A3)
External links
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
This article is issued from Wikipedia - version of the Wednesday, December 16, 2015. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.